Burow Kristina

Average Profitability
59.17%
Insider Buys Quantity
16
Insider Buys Sum
$71.43M
Insider Sells Quantity
0
Insider Sells Sum
$0

Insider Activity of Burow Kristina

The largest purchase of all time was on 2019-10-16 and amounted to 2000000 shares of Vir Biotechnology, Inc. for $40M.

Biography of Burow Kristina

No biography is available at this moment.

2023-11-14PurchaseNeumora Therapeutics, Inc. Common Stock
NMRA
3,357
0.0025%
$11.98$40,217+3.37%
2023-11-13PurchaseNeumora Therapeutics, Inc. Common Stock
NMRA
31,653
0.0232%
$11.75$371,923+2.51%
2023-11-10PurchaseNeumora Therapeutics, Inc. Common Stock
NMRA
17,275
0.0124%
$11.49$198,481+5.87%
2023-11-09PurchaseNeumora Therapeutics, Inc. Common Stock
NMRA
31,079
0.0204%
$10.53$327,262+15.57%
2023-11-08PurchaseNeumora Therapeutics, Inc. Common Stock
NMRA
92,251
0.0634%
$11.03$1.02M+15.05%
2023-11-07PurchaseNeumora Therapeutics, Inc. Common Stock
NMRA
30,192
0.0216%
$11.50$347,208+5.26%
2023-11-06PurchaseNeumora Therapeutics, Inc. Common Stock
NMRA
43,082
0.031%
$11.55$497,597+6.66%
2023-11-03PurchaseNeumora Therapeutics, Inc. Common Stock
NMRA
22,420
0.0159%
$11.38$255,140+2.7%
2023-09-29PurchaseNeumora Therapeutics, Inc. Common Stock
NMRA
34,560
0.0301%
$13.98$483,149-15.59%
2023-09-28PurchaseNeumora Therapeutics, Inc. Common Stock
NMRA
41,951
0.0351%
$13.44$563,699-9.91%
2023-09-27PurchaseNeumora Therapeutics, Inc. Common Stock
NMRA
24,504
0.0188%
$12.31$301,644+0.76%
2023-09-26PurchaseNeumora Therapeutics, Inc. Common Stock
NMRA
34,000
0.0248%
$11.73$398,820+1.71%
2023-09-25PurchaseNeumora Therapeutics, Inc. Common Stock
NMRA
60,740
0.0424%
$11.22$681,464+4.43%
2023-09-22PurchaseNeumora Therapeutics, Inc. Common Stock
NMRA
40,000
0.0277%
$11.14$445,600+7.62%
2023-09-19PurchaseNeumora Therapeutics, Inc. Common Stock
NMRA
1.5M
1.5879%
$17.00$25.5M-1.04%
2019-10-16PurchaseVir Biotechnology, Inc.
VIR
director
2M
8.9051%
$20.00$40M+115.34%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.